文献速递产科麻醉区域麻醉与超声疼痛医学

鞘内氢吗啡酮与吗啡用于剖宫产术后镇痛的非劣效性随机试验

Intrathecal Hydromorphone Versus Intrathecal Morphine for Postcesarean Delivery Analgesia: A Randomized Noninferiority Trial.
PubMed 文献 · Anesth Analg · 2025-06-10

这项非劣效性随机盲法临床试验纳入126例择期剖宫产脊麻患者,分别给予鞘内吗啡150 µg或氢吗啡酮75 µg(均为ED90)。主要结局为术后24小时平均NRS疼痛评分组间差,非劣效界值为1。结果显示氢吗啡酮组24小时NRS为3.6(1.5),吗啡组为4.0(1.7),组间差-0.46(95%CI -1.0至0.1),95%CI上限未超过1,氢吗啡酮非劣效成立;24小时口服吗啡消耗量、恢复质量、首次阿片请求时间及副作用干预比例均无统计学差异。

要点

  • 鞘内氢吗啡酮75 µg在剖宫产术后24小时镇痛上非劣效于吗啡150 µg。
  • 两组24小时口服吗啡消耗量、ObsQoR-11评分及首次阿片请求时间均无显著差异。
  • 氢吗啡酮可作为鞘内吗啡的合适替代选择,尤其面对药物短缺时。

核心结论

  • 择期剖宫产脊麻下,鞘内氢吗啡酮75 µg在术后24小时镇痛方面非劣效于鞘内吗啡150 µg(两者均为ED90)。
  • 氢吗啡酮提供有效镇痛,可能是吗啡的合适替代选择。

研究设计与样本

  • 非劣效性随机盲法临床试验,共126例在脊麻下接受择期剖宫产的患者。
  • 患者随机接受鞘内吗啡150 µg或氢吗啡酮75 µg(均为ED90)。
  • 主要结局为术后24小时平均NRS疼痛评分(0-10)的组间差,非劣效界值为1。

主要发现

  • 24小时NRS疼痛评分均值(SD):吗啡4.0(1.7),氢吗啡酮3.6(1.5),组间差-0.46(95%CI -1.0至0.1)。
  • 24小时口服吗啡消耗量均值(SD):吗啡4.2 mg(6.5)vs氢吗啡酮4.1 mg(8.0),P=.98。
  • ObsQoR-11评分中位数[IQR]:吗啡87[75-97.5]vs氢吗啡酮90[80-96.5],P=.51。
  • 首次阿片请求时间中位数[IQR]:吗啡10.2[3.2-15.5]h vs氢吗啡酮6.2[3.1-12.4]h,P=.35。
  • 阿片相关瘙痒干预比例:吗啡0.316(方差0.216)vs氢吗啡酮0.321(方差0.218),P=.96;恶心呕吐干预比例:吗啡0.333(方差0.222)vs氢吗啡酮0.393(方差0.238),P=.51。

关键数值与推荐

  • 非劣效界值为24小时NRS疼痛评分组间差不超过1。
  • 氢吗啡酮组95%CI上限为0.1,未超过非劣效界值1,非劣效性成立。
  • 鞘内吗啡剂量150 µg、氢吗啡酮剂量75 µg,均为各自ED90。

临床怎么用

  • 在择期剖宫产脊麻中,可考虑以鞘内氢吗啡酮75 µg替代吗啡150 µg用于术后镇痛。
  • 在吗啡短缺或副作用顾虑时,氢吗啡酮是可选替代方案。

局限性

  • 24小时NRS疼痛评分为术后24小时访谈时基于患者回忆的总体疼痛体验单一数值。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spinal anesthesia with intrathecal morphine is often the preferred anesthetic modality for elective cesarean delivery. Side effects and drug shortages, however, prompted researchers to look into intrathecal hydromorphone as an alternative. These studies established the effective analgesic dose for 90% of patients (ED90) for both opioids for postcesarean analgesia, yet failed to demonstrate the superiority of morphine over hydromorphone. Nonetheless, the noninferiority of hydromorphone has yet to be determined. METHODS: In this noninferiority randomized blinded clinical trial, 126 patients undergoing elective cesarean delivery under spinal anesthesia received either morphine 150 µg or hydromorphone 75 µg (ED90). The primary outcome was the between-group difference of the mean Numeric Rating Scale (NRS) pain score (0-10) for the first 24 hours after cesarean delivery, with a preestablished threshold for noninferiority of 1. This 24-hour NRS pain score was defined as a single number obtained at the 24 hours postcesarean delivery interview, based on participant's recall of their overall pain experience during this period. Secondary outcomes included differences in NRS pain scores every 6 hours, cumulative 24 hour opioid consumption, time-to-first opioid request, quality of recovery as measured by the Obstetric Quality of Recovery Score-11 (ObsQoR-11), frequency of interventions for side effects, and Apgar scores. RESULTS: The mean (standard deviation [SD]) of the 24-hour NRS pain score was 4.0 (1.7) for morphine and 3.6 (1.5) for hydromorphone (between-group difference -0.46 (95% confidence interval [CI], -1.0 to 0.1). Given that the upper limit of the 95% CI did not exceed 1, noninferiority of hydromorphone was established. No statistically significant differences were found in mean (SD) 24 hour oral morphine consumption (morphine: 4.2 mg (6.5) vs hydromorphone: 4.1 (8.0) mg; P = .98), median [interquartile range {IQR}] ObsQoR-11 score (morphine: score 87 [75-97.5] vs hydromorphone: score 90 [80-96.5]; P = .51), median [IQR] time to first opioid request (morphine: 10.2 [3.2-15.5] h versus hydromorphone: 6.2 [3.1-12.4] h; P = .35), or proportion of patients requiring interventions for opioid-related pruritus (morphine: 0.316 (variance 0.216) vs hydromorphone: 0.321 (variance 0.218) ( P = .96) and opioid-related nausea and vomiting (morphine: 0.333 (variance 0.222) vs hydromorphone: 0.393 (variance 0.238) ( P = .51). CONCLUSIONS: Intrathecally, hydromorphone is noninferior to morphine for analgesia after elective cesarean delivery when using the previously established ED90 for both opioids (morphine: 150 µg versus hydromorphone: 75 µg); hydromorphone provides effective analgesia and may be a suitable alternative to morphine.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Cheng S, Bartolacci J, Armstrong K, et al. Intrathecal Hydromorphone Versus Intrathecal Morphine for Postcesarean Delivery Analgesia: A Randomized Noninferiority Trial. Anesth Analg. 2025. PMID: 40493496. doi:10.1213/ANE.0000000000007580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。